Financhill
Sell
24

BIOLQ Quote, Financials, Valuation and Earnings

Last price:
$0.0100
Seasonality move :
28.19%
Day range:
$0.0075 - $0.0098
52-week range:
$0.0040 - $1.2700
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.00x
P/B ratio:
--
Volume:
16.8K
Avg. volume:
119.5K
1-year change:
-99.35%
Market cap:
$274.5K
Revenue:
$49.2M
EPS (TTM):
-$2.04

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BIOLQ
Biolase
$13.5M -$0.01 3.78% -99.9% --
ALGN
Align Technology
$990.5M $2.31 4.86% 48.7% $264.08
MLSS
Milestone Scientific
$2.6M -$0.01 17.38% -66.67% --
NVST
Envista Holdings
$590.3M $0.09 0.24% -26.93% $21.33
WCUI
Wellness Center USA
-- -- -- -- --
XRAY
Dentsply Sirona
$939.9M $0.48 -8.87% 36.37% $22.96
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BIOLQ
Biolase
$0.0075 -- $274.5K -- $0.00 0% 0.00x
ALGN
Align Technology
$213.50 $264.08 $15.9B 36.43x $0.00 0% 4.06x
MLSS
Milestone Scientific
$0.85 -- $66.2M -- $0.00 0% 7.51x
NVST
Envista Holdings
$18.95 $21.33 $3.3B -- $0.00 0% 1.31x
WCUI
Wellness Center USA
$0.0005 -- $71.6K -- $0.00 0% 0.16x
XRAY
Dentsply Sirona
$18.90 $22.96 $3.8B -- $0.16 3.28% 1.00x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BIOLQ
Biolase
142.17% 5.184 714.45% 0.23x
ALGN
Align Technology
-- 3.151 -- 1.07x
MLSS
Milestone Scientific
-- 1.592 -- 1.42x
NVST
Envista Holdings
31.63% 0.099 41.83% 1.60x
WCUI
Wellness Center USA
-- 4.433 -- --
XRAY
Dentsply Sirona
47.09% 0.353 41.22% 0.63x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BIOLQ
Biolase
$4.4M -$695K -129.74% -21668.17% -7.48% -$4.5M
ALGN
Align Technology
$681.8M $162.4M 11.69% 11.69% 16.6% $233.9M
MLSS
Milestone Scientific
$1.8M -$1.5M -61.33% -61.33% -58.44% -$973.9K
NVST
Envista Holdings
$317.3M $20.9M -25.62% -35.84% 3.58% $63.3M
WCUI
Wellness Center USA
-- -- -- -- -- --
XRAY
Dentsply Sirona
$495M $64M -7.95% -13.34% -48.37% $98M

Biolase vs. Competitors

  • Which has Higher Returns BIOLQ or ALGN?

    Align Technology has a net margin of -13.16% compared to Biolase's net margin of 11.86%. Biolase's return on equity of -21668.17% beat Align Technology's return on equity of 11.69%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    ALGN
    Align Technology
    69.72% $1.55 $3.9B
  • What do Analysts Say About BIOLQ or ALGN?

    Biolase has a consensus price target of --, signalling upside risk potential of 26566.67%. On the other hand Align Technology has an analysts' consensus of $264.08 which suggests that it could grow by 23.69%. Given that Biolase has higher upside potential than Align Technology, analysts believe Biolase is more attractive than Align Technology.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    0 0 0
    ALGN
    Align Technology
    7 6 0
  • Is BIOLQ or ALGN More Risky?

    Biolase has a beta of 0.923, which suggesting that the stock is 7.737% less volatile than S&P 500. In comparison Align Technology has a beta of 1.657, suggesting its more volatile than the S&P 500 by 65.668%.

  • Which is a Better Dividend Stock BIOLQ or ALGN?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Align Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Align Technology pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or ALGN?

    Biolase quarterly revenues are $10.9M, which are smaller than Align Technology quarterly revenues of $977.9M. Biolase's net income of -$1.4M is lower than Align Technology's net income of $116M. Notably, Biolase's price-to-earnings ratio is -- while Align Technology's PE ratio is 36.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 4.06x for Align Technology. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    ALGN
    Align Technology
    4.06x 36.43x $977.9M $116M
  • Which has Higher Returns BIOLQ or MLSS?

    Milestone Scientific has a net margin of -13.16% compared to Biolase's net margin of -58.13%. Biolase's return on equity of -21668.17% beat Milestone Scientific's return on equity of -61.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    MLSS
    Milestone Scientific
    73.05% -$0.02 $7.2M
  • What do Analysts Say About BIOLQ or MLSS?

    Biolase has a consensus price target of --, signalling upside risk potential of 26566.67%. On the other hand Milestone Scientific has an analysts' consensus of -- which suggests that it could grow by 150%. Given that Biolase has higher upside potential than Milestone Scientific, analysts believe Biolase is more attractive than Milestone Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    0 0 0
    MLSS
    Milestone Scientific
    0 0 0
  • Is BIOLQ or MLSS More Risky?

    Biolase has a beta of 0.923, which suggesting that the stock is 7.737% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 1.097, suggesting its more volatile than the S&P 500 by 9.734%.

  • Which is a Better Dividend Stock BIOLQ or MLSS?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or MLSS?

    Biolase quarterly revenues are $10.9M, which are larger than Milestone Scientific quarterly revenues of $2.5M. Biolase's net income of -$1.4M is higher than Milestone Scientific's net income of -$1.5M. Notably, Biolase's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 7.51x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    MLSS
    Milestone Scientific
    7.51x -- $2.5M -$1.5M
  • Which has Higher Returns BIOLQ or NVST?

    Envista Holdings has a net margin of -13.16% compared to Biolase's net margin of 1.36%. Biolase's return on equity of -21668.17% beat Envista Holdings's return on equity of -35.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    NVST
    Envista Holdings
    52.8% $0.05 $4.5B
  • What do Analysts Say About BIOLQ or NVST?

    Biolase has a consensus price target of --, signalling upside risk potential of 26566.67%. On the other hand Envista Holdings has an analysts' consensus of $21.33 which suggests that it could grow by 12.58%. Given that Biolase has higher upside potential than Envista Holdings, analysts believe Biolase is more attractive than Envista Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    0 0 0
    NVST
    Envista Holdings
    3 10 1
  • Is BIOLQ or NVST More Risky?

    Biolase has a beta of 0.923, which suggesting that the stock is 7.737% less volatile than S&P 500. In comparison Envista Holdings has a beta of 1.315, suggesting its more volatile than the S&P 500 by 31.484%.

  • Which is a Better Dividend Stock BIOLQ or NVST?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or NVST?

    Biolase quarterly revenues are $10.9M, which are smaller than Envista Holdings quarterly revenues of $601M. Biolase's net income of -$1.4M is lower than Envista Holdings's net income of $8.2M. Notably, Biolase's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 1.31x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    NVST
    Envista Holdings
    1.31x -- $601M $8.2M
  • Which has Higher Returns BIOLQ or WCUI?

    Wellness Center USA has a net margin of -13.16% compared to Biolase's net margin of --. Biolase's return on equity of -21668.17% beat Wellness Center USA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    WCUI
    Wellness Center USA
    -- -- --
  • What do Analysts Say About BIOLQ or WCUI?

    Biolase has a consensus price target of --, signalling upside risk potential of 26566.67%. On the other hand Wellness Center USA has an analysts' consensus of -- which suggests that it could fall by --. Given that Biolase has higher upside potential than Wellness Center USA, analysts believe Biolase is more attractive than Wellness Center USA.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    0 0 0
    WCUI
    Wellness Center USA
    0 0 0
  • Is BIOLQ or WCUI More Risky?

    Biolase has a beta of 0.923, which suggesting that the stock is 7.737% less volatile than S&P 500. In comparison Wellness Center USA has a beta of 1.668, suggesting its more volatile than the S&P 500 by 66.753%.

  • Which is a Better Dividend Stock BIOLQ or WCUI?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Wellness Center USA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Wellness Center USA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or WCUI?

    Biolase quarterly revenues are $10.9M, which are larger than Wellness Center USA quarterly revenues of --. Biolase's net income of -$1.4M is higher than Wellness Center USA's net income of --. Notably, Biolase's price-to-earnings ratio is -- while Wellness Center USA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 0.16x for Wellness Center USA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    WCUI
    Wellness Center USA
    0.16x -- -- --
  • Which has Higher Returns BIOLQ or XRAY?

    Dentsply Sirona has a net margin of -13.16% compared to Biolase's net margin of -51.95%. Biolase's return on equity of -21668.17% beat Dentsply Sirona's return on equity of -13.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    XRAY
    Dentsply Sirona
    52.05% -$2.46 $4.7B
  • What do Analysts Say About BIOLQ or XRAY?

    Biolase has a consensus price target of --, signalling upside risk potential of 26566.67%. On the other hand Dentsply Sirona has an analysts' consensus of $22.96 which suggests that it could grow by 21.5%. Given that Biolase has higher upside potential than Dentsply Sirona, analysts believe Biolase is more attractive than Dentsply Sirona.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    0 0 0
    XRAY
    Dentsply Sirona
    4 8 0
  • Is BIOLQ or XRAY More Risky?

    Biolase has a beta of 0.923, which suggesting that the stock is 7.737% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.965, suggesting its less volatile than the S&P 500 by 3.545%.

  • Which is a Better Dividend Stock BIOLQ or XRAY?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 3.28% to investors and pays a quarterly dividend of $0.16 per share. Biolase pays -- of its earnings as a dividend. Dentsply Sirona pays out -87.88% of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or XRAY?

    Biolase quarterly revenues are $10.9M, which are smaller than Dentsply Sirona quarterly revenues of $951M. Biolase's net income of -$1.4M is higher than Dentsply Sirona's net income of -$494M. Notably, Biolase's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 1.00x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    XRAY
    Dentsply Sirona
    1.00x -- $951M -$494M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is SoundHound AI Stock Up So Much?
Why Is SoundHound AI Stock Up So Much?

Like many companies improving AI technologies and exploring ways to…

Is The Santa Claus Rally The Gift That Keeps Giving?
Is The Santa Claus Rally The Gift That Keeps Giving?

Remember the horror of 2008 when the Great Recession hit…

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
87
PSIX alert for Dec 26

Power Solutions International [PSIX] is up 0.98% over the past day.

Buy
65
TSLL alert for Dec 26

Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.9% over the past day.

Buy
75
SMLR alert for Dec 26

Semler Scientific [SMLR] is down 1.42% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock